:quality(70))
From ASCO insights to smarter trial decisions
ASCO 2026 marked an important transition in oncology. Rather than showcasing isolated advances, the meeting demonstrated how precision medicine, targeted therapies, immunotherapy, individualized treatments and emerging technologies are increasingly converging to reshape both cancer care and clinical development. This webinar explores what those developments mean for oncology clinical trial strategy, operational planning and patient access.
Promising data challenged long-standing assumptions from targeting previously “undruggable” cancer biology and advancing personalized cancer vaccines to using genomic information to safely reduce treatment intensity. At the same time, bispecific antibodies, novel immune-based approaches and AI-enabled tools continued to move closer to routine clinical application.
However, scientific progress alone does not guarantee successful development or patient access.
In this webinar, oncology experts will examine key highlights from ASCO 2026 through four complementary perspectives: the clinical research site, the CRO, the sponsor, and the principal investigator. The discussion will explore how emerging evidence may influence development strategies, protocol design, biomarker and patient-selection approaches, site feasibility, recruitment, treatment delivery, safety oversight, data quality and the overall patient experience.
By bringing strategic, operational and clinical viewpoints together, the webinar will move beyond the headlines to consider what these advances mean in practice and what sponsors, sites and investigators must do differently to translate increasingly personalized and complex oncology science into efficient clinical trials and meaningful patient benefits.